Quantum computing might be the newest buzzword, but it also might represent the chief disruptive technology through 2040. Forward-looking leaders in biopharma R&D will appreciate Boston Consulting Group’s white paper outlining quantum computing’s potential uses and impacts in drug development. Matt Langione, Jean-François Bobier, Chris Meier, Sebastian Hasenfuss and Ulrik Schulze outline the technology’s potential and urge biopharma leaders to begin preparing now.
About the Authors
Matt Langione is a project leader, Jean-François Bobier is a partner and associate director, Christoph Meier is a principal, and Sebastian Hasenfuss is a consultant at the Boston Consulting Group. Ulrik Schulze, a managing director and senior partner at BCG, leads the firm’s global biopharmaceutical sector.
Comment on this summary
By the same authors
In our Journal
2 years ago
Quantum Computing Gets Real
Quantum mechanics is turbocharging computing. What does it mean for your business? Quantum mechanics disrupted classical physics when, in the early 20th century, Niels Bohr first described the ways that atomic behavior diverges from the behavior of larger matter. When science journalist Julian Brown wrote Minds, Machines, and the Multiverse in 2000, quantum computing was […]
3 years ago
How the Pandemic is Accelerating Digital Transformation
The coronavirus pandemic and the need to avoid person-to-person interactions has pushed us further into a digital world. The crisis will have lasting effects on the way we work, do business and interact with each other. Up until now, companies have embraced digital transformation at an uneven pace and rate of success. A majority of […]